Proline analogs as ligands for cannabinoid receptors

Details Proline analogs as ligands for cannabinoid receptors Proline analogs as ligands for cannabinoid receptors

2009-01-08

2011-12-27

Anderson, Rebecca (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S525000

Reexamination Certificate

active

08084612

ABSTRACT:
The invention relates to compounds of Formulae I(a) to XIand pharmaceutically acceptable salts and solvates thereof (Proline Analog Compounds), that are useful, e.g., as ligands for cannabinoid receptors, as compositions comprising a Proline Analog Compound and a pharmaceutically acceptable carrier, in methods of making such Proline Analog Compounds, and in methods for treating or preventing a Condition, such as pain, nausea, vomiting and an eating disorder, comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof.

REFERENCES:
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5922740 (1999-07-01), Braunlich et al.
patent: 6136839 (2000-10-01), Isakson et al.
patent: 6271252 (2001-08-01), Chang et al.
patent: 6852748 (2005-02-01), Kelly et al.
patent: 2007/0287744 (2007-12-01), Barth et al.
patent: 2008634 (1989-07-01), None
patent: WO 93/19070 (1993-09-01), None
patent: WO 99/26615 (1999-03-01), None
patent: WO 2004/012671 (2004-02-01), None
patent: WO 2004/041273 (2004-05-01), None
patent: WO 2005/115977 (2005-12-01), None
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.” Advanced Drug Delivery Reviews 2004, 56, 275-300.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
ACS on STN, list of 20 compounds, dated Mar. 21, 2008.
ACS on STN list of 20 compounds, dated Mar. 21, 2008.
Ahmad et al., “Novel G protein-coupled receptors as pain targets,”Curr. Opin. Invest. Drugs5(1):67-70 (2004).
Bagshaw, “Medical Efficacy of Cannabinoids and Marijuana: a Comprehensive Review of the Literature,”J. Palliative Care18(2):111-122 (2002).
Black, “Cannabinoid receptor antagonists and obesity,”Curr. Opin. Investig. Drugs5(4):389-394 (2004).
Buchwald et al., “Long-term, Continuous Intravenous Heparin Administration by an Implantable Infusion Pump in Ambulatory Patients with Recurrent Venous Thrombosis,”Surgery88:507-516 (1980).
Chang et al., “Highly constrained bicyclic VLA-4 antagonists,”Bioorganic&Med. Chem Let. 17:597-601 (2007).
Cheng et al., “Relationship between the inhibition constant, Ki, and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction,”Biochem. Pharmacol. 22:3099-3108 (1973).
Cichewicz, “Synergistic interactions between cannabinoid and opioid analgesics,”Life Sciences74:1317-1324 (2004).
Croxford, “Therapeutic potential of cannabinoids in CNS disease,”CNS Drugs17(3):179-202 (2003).
During et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,”Ann. Neurol. 25:351-356 (1989).
Fernandez et al., “Rimonabant,”Curr. Opin. Investig. Drugs5(4):430-435 (2004).
Goodson, “Dental Applications,” pp. 115-138 inMedical Applications of Controlled Release, vol. 2 , Applications and Evaluation, Langer and Wise, Eds., CRC Press (1984).
Grotenhermen, “Pharmacology of Cannabinoids,”Neuroendocrinol. Lett. 25(1/2):14-23 (2004).
Hanson, “Analgesic, Antipyretic and Anti-Inflammatory Drugs,” pp. 1196-1221 inRemington: The Science and Practice of Pharmacy, vol. 2 (Gennaro Ed. 19thEd. 1995).
Howard et al., “Intracerebral drug delivery in rats with lesion-induced memory deficits,”J Neurosurg. 71:105 (1989).
Howlett “International Union of Pharmacology. XXVII. Classification of cannabinoid receptors,”Pharmacol. Rev. 54(2):161-202 (2002).
Howlett, “The cannabinoid receptors,”Prostaglandins and other Lipid Mediators68-69:619-631 (2002).
Insel, “Analgesic-Antipyretic and Anti-inflammatory Agents and Drugs Employed in the Treatment of Gout,” inGoodman&Gilman's The Pharmacological Basis of Therapeuticspp. 617-657 (Goodman et al., eds., 9thed., McGraw-Hill, New York 1996).
Lange et al., “Recent advances in CB1 cannabinoid receptor antagonists,”Curr. Opin. Drug Disc.&Devel. 7(4):498-506 (2004).
Langer et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,”J. Macromol. Sci. Rev. Macromol. Chem. C23(1):61-126 (1983).
Langer et al., “Classes of Systems,”Medical Applications of Controlled Releasevol. I, CRC Press, Boca Raton, FL (1984).
Langer, “New Methods of Drug Delivery,”Science249:1527-1533 (1990).
Levy, “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,”Science228:190-192 (1985).
Mackie et al., “Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor,”J. Neurosci15(10):6552-6561 (1995).
Neff et al., “Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease,”Am. J. Gastroenterol. 97(8):2117-2119 (2002).
PCT International Search Report for International Application No. PCT/IB2009/000023 dated Apr. 21, 2009.
Pertwee et al., “Cannabinoid receptors and their ligands,”Prostaglandins, Leukotrienes and Essential Fatty Acids66(2&3):101-121 (2002).
Piomelli, “The molecular logic of endo-cannabinoid signaling,”Nature Revs. (Neuroscience) 4:873-884 (2003).
Radebough et al., “Preformulation,” pp. 1447-1676 inRemington's Pharmaceutical Sciences(Gennaro, Ed., 19thEd., 1995).
Ross et al., “Pharmacodynamics: Mechanisms of Drug Action and the Relationship Between Drug Concentration and Effect,” inGoodman&Gilman's the Pharmacological Basis of TherapeuticsChapter 2, pp. 31-32 (Hardman et al., eds., 10thed., McGraw-Hill, New York 2001).
Saudek et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery,”New Engl. J. Med. 321:574-579 (1989).
Sefton, “Implantable Pumps,”CRC Crit. Rev. Biomed. Eng. 14(3):201-240 (1987).
Smolen et al., “Drug Product Design and Performance,”Controlled Drug Bioavailabilityvol. 1, John Wiley & Sons, New York (1984).
Tomida et al., “Cannabinoids and glaucoma,”Br. J. Ophthalmol. 88:708-713 (2003).
Treat et al., “Liposome Encapsulated Doxorubicin Preliminary Results of Phase I and Phase II Trials,”Liposomes in the Therapy of Infectious Disease and Cancerpp. 317-327 and 353-365 (1989).
Walker et al. “Cannabinoid analgesia,”Pharmacol. Therapeut. 95:127-135 (2002).

Affiliated with

Also associated with

Rating

Proline analogs as ligands for cannabinoid receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Proline analogs as ligands for cannabinoid receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proline analogs as ligands for cannabinoid receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4309257